ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors

Annals of the Rheumatic Diseases

Volumn 70, Issue 8, 2011, Pages 1375-1381

  Pedersen, Susanne Juhl ^a,b   Sørensen, Inge Juul ^b,c   Garnero, Patrick ^d,e   Johansen, Julia Sidenius ^a   Madsen, Ole Rintek ^b   Tvede, Niels ^e   Hansen, Michael Sejer ^b   Thamsborg, Gorm ^b   Andersen, Lis Smedegaard ^f   Majgaard, Ole ^c   Loft, Anne Gitte ^g   Erlendsson, Jon ^h   Asmussen, Karsten ⁱ   Jurik, Anne Grethe ^j   Møller, Jakob ^a   Hasselquist, Maria ^a   Mikkelsen, Dorrit ^k   Skjødt, Thomas ^g   Lambert, Robert ^l   Hansen, Annette ^e   Østergaard, Mikkel ^c   more..

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d INSERM   (France)

^e INSERM Unit 664 ^*  (Denmark)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^g LILLEBAELT HOSPITAL   (Denmark)

^h HORSENS REGIONAL HOSPITAL   (Denmark)

ⁱ BISPEBJERG HOSPITAL   (Denmark)

^j AARHUS UNIVERSITY HOSPITAL   (Denmark)

^k Hospital of Southern Jutland   (Denmark)

^l UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AGGRECAN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; C TERMINAL CROSSLINKING TELOPEPTIDE OF TYPE II COLLAGEN; CARBOXY TERMINAL TELOPEPTIDE; CARTILAGE OLIGOMERIC MATRIX PROTEIN; COLLAGEN TYPE 2; ETANERCEPT; GLYCOPROTEIN; INFLIXIMAB; INTERLEUKIN 6; OSTEOCALCIN; PROTEIN YKL 40; STROMELYSIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTICLE; AXIAL SPONDYLOARTHRITIS; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BONE TURNOVER; CARTILAGE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SPONDYLITIS; TREATMENT RESPONSE;

ADULT; ANGIOGENESIS INDUCING AGENTS; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; BONE REMODELING; C-REACTIVE PROTEIN; CARTILAGE, ARTICULAR; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 79959802664     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.138883     Document Type: Article

References (32)

1. Bal A, Unlu E, Bahar G, et al. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007;26:211-15. (Pubitemid 46020247)
2. Maksymowych WP, Jhangri GS, Lambert RG, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002;29:959-65. (Pubitemid 34493501)
3. Maksymowych WP, Poole AR, Hiebert L, et al. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 2005;32:1911-17. (Pubitemid 41429021)
4. Visvanathan S, Wagner C, Marini JC, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008;67:511-17. (Pubitemid 351498433)
5. Appel H, Janssen L, Listing J, et al. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Res Ther 2008;10:R125.
6. Drouart M, Saas P, Billot M, et al. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 2003;132:158-62. (Pubitemid 36418919)
7. Briot K, Roux C, Gossec L, et al. Effects of etanercept on serum biochemical markers of cartilage metabolism in patients with spondyloarthropathy. J Rheumatol 2008; 35:310-14. (Pubitemid 351281153)
8. Kruithof E, De Rycke L, Vandooren B, et al. Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum 2006;54:1795-804. (Pubitemid 43877929)
9. Maksymowych WP, Rahman P, Shojania K, et al. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol 2008;35:2030-7.
10. Vandooren B, Kruithof E, Yu DT, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 2004;50:2942-53. (Pubitemid 39209533)
11. Allali F, Breban M, Porcher R, et al. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 2003;62:347-9. (Pubitemid 36363442)
12. Visvanathan S, van der Heijde D, Deodhar A, et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:175-82.
13. Woo JH, Lee HJ, Sung IH, et al. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007;34:1753-9.
14. Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18-24.
15. van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811-18.
16. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
17. Pedersen SJ, Sørensen IJ, Hermann KG, et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2010;69:1065-71.
18. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
19. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8. (Pubitemid 14134775)
20. Puhakka KB, Jurik AG, Egund N, et al. Imaging of sacroiliitis in early seronegative spondylarthropathy. Assessment of abnormalities by MR in comparison with radiography and CT. Acta Radiol 2003;44:218-29.
21. Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24. (Pubitemid 37026490)
22. Machado P, Landewé R, Lie E, et al. Ankylosing spondylitis disease activity score (ASDAS): defining criteria for disease activity states and improvement scores. Ann Rheum Dis 2010;69 ( Suppl 3 ): 96.
23. Husted JA, Cook RJ, Farewell VT, et al. Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 2000;53:459-68. (Pubitemid 30254341)
24. de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 2009;61:1484-90.
25. Rudwaleit M, Baraliakos X, Listing J, et al. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis 2005;64:1305-10. (Pubitemid 41206247)
26. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-73. (Pubitemid 43139720)
27. Sumer EU, Sondergaard BC, Rousseau JC, et al. MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays. Osteoarthr Cartil 2007;15:212-21. (Pubitemid 46132104)
28. Rudwaleit M, Jurik AG, Hermann KG, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 2009;68:1520-7.
29. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777-83.
30. Knudsen LS, Christensen IJ, Lottenburger T, et al. Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers 2008;13:59-78.
31. Hetland ML, Christensen IJ, Lottenburger T, et al. Circulating VEGF as a biological marker in patients with rheumatoid arthritis? Preanalytical and biological variability in healthy persons and in patients. Dis Markers 2008;24:1-10. (Pubitemid 350174565)
32. Johansen JS, Lottenburger T, Nielsen HJ, et al. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev 2008;17:2603-8.